



e-ISSN: 2319-8753 | p-ISSN: 2347-6710

# IJIRSET

International Journal of Innovative Research in  
**SCIENCE | ENGINEERING | TECHNOLOGY**

# INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

Volume 13, Issue 5, May 2024

**ISSN** INTERNATIONAL  
STANDARD  
SERIAL  
NUMBER  
INDIA

Impact Factor: 8.423

9940 572 462

6381 907 438

[ijirset@gmail.com](mailto:ijirset@gmail.com)

[www.ijirset.com](http://www.ijirset.com)

# An Overview of Trilaciclib: Its Drug Profile and Applications in Treating Lung Cancer

Pathan Daud Ahmed Khan, Pathan Saheba Ahmed Khan

P.G. Student, Department of Quality Assurance, MCE's Allana College of Pharmacy, Pune, India

U. G Student, B. Pharmacy, Swami Vivekanand College of Pharmacy, Udgir, Latur, India

**ABSTRACT:** Trilaciclib, marketed as Cosela, is a groundbreaking medication designed to alleviate the side effects of chemotherapy-induced bone marrow suppression. Chemotherapy, while effective against cancer cells, often damages normal tissues, including the bone marrow, leading to myelosuppression and its associated complications. Trilaciclib inhibits cyclin-dependent kinase 4/6, safeguarding bone marrow cells from chemotherapy-induced damage. This enables cancer patients to undergo chemotherapy without experiencing bone marrow suppression and its adverse effects. Trilaciclib's approval by the FDA signifies its safety and efficacy, providing hope for cancer patients worldwide. This drug profile outlines Trilaciclib's pharmacological properties, mechanism of action, absorption, metabolism, and potential adverse effects. Additionally, it highlights Trilaciclib's applications in managing chemotherapy-induced myelosuppression, preventing neutropenia, improving chemotherapy tolerance, facilitating combination chemotherapy regimens, and enhancing post-chemotherapy recovery. Trilaciclib represents a significant advancement in supportive cancer care, promising to improve treatment outcomes and quality of life for patients undergoing chemotherapy.

**KEYWORDS:** Trilaciclib, Cosela, chemotherapy-induced myelosuppression, bone marrow suppression, CDK4/6 inhibitor, cancer treatment, supportive care, hematologic toxicity, neutropenia prevention, chemotherapy tolerance, combination chemotherapy regimens, post-chemotherapy recovery, FDA approval, quality of life, cancer therapeutics.

## I. INTRODUCTION

Trilaciclib, which is sold under the brand name Cosela, is a revolutionary medication that has been developed to alleviate the side effects of chemotherapy-induced bone marrow suppression. The bone marrow is an essential part of the human body that produces white blood cells, red blood cells, and platelets. These cells are responsible for transporting oxygen, fighting infection, and stopping bleeding. Chemotherapy drugs are effective in killing cancer cells, but they can also damage normal tissues, including the bone marrow, which can cause a range of side effects such as fatigue, increased risk of infection and bleeding, and other problems. Trilaciclib is a first-in-class medication that works by inhibiting cyclin-dependent kinase 4/6, a type of enzyme that plays a crucial role in cell division. By inhibiting this enzyme, Trilaciclib helps protect the normal bone marrow cells from the harmful effects of chemotherapy. This means that cancer patients can undergo chemotherapy without experiencing bone marrow suppression and its associated side effects. The typical adverse reactions associated with Trilaciclib comprise fatigue, reduced calcium, potassium, and phosphate levels, elevated aspartate aminotransferase levels, headaches, and lung infections such as pneumonia. These side effects are mild and temporary and can be managed with proper care and guidance from healthcare professionals. The development of Trilaciclib has been a breakthrough in the field of cancer treatment. It has provided cancer patients with a new hope for a better quality of life and increased survival rates. Moreover, the U.S. Food and Drug Administration has approved Trilaciclib for use in the United States, which indicates the medication's safety and effectiveness. Thus, Trilaciclib is a medication that has revolutionized cancer treatment. It has proven to be an effective tool in reducing the side effects of chemotherapy-induced bone marrow suppression, which is a major concern in cancer treatment. Its approval by the U.S. Food and Drug Administration is a testament to its safety and effectiveness, and it provides hope for cancer patients worldwide..




## II. DRUG PROFILE

**Name:** Trilaciclib

**Description:**

Trilaciclib, also known as G1T28, is a promising drug that acts as a CDK4 and CDK6 inhibitor. It has been developed to reduce the occurrence of chemotherapy-induced myelosuppression in patients who are about to receive topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer. CDK4 and CDK6 inhibitors have been under investigation since the mid-1990s for their potential use in treating cancer and enhancing the efficacy of chemotherapy. Trilaciclib came into the limelight in 2016 when it was first described in the literature. After years of rigorous pre-clinical and clinical development, Trilaciclib was finally granted approval by the FDA on February 12th, 2021. This approval marks a significant milestone for cancer patients and offers new hope to those suffering from small-cell lung cancer.

**Structure:**



**CAS number:** 1374743-00-6

**Molecular Weight:**

Average: 446.559

Monoisotopic: 446.254257618

**Chemical Formula:** C<sub>24</sub>H<sub>30</sub>N<sub>8</sub>O

**IUPAC Name:**

12'-{[5-(4-methyl piperazine-1-yl)pyridin-2-yl]amino}-2',5',11',13'-tetraazaspiro[cyclohexane-1,3'-tricyclo[7.4.0.0<sup>2,7</sup>]tridecane]-1'(9'),7',10',12'-tetraen-6'-one

**PHARMACOLOGY:**

**Indication:**

Trilaciclib is a medication that is specifically designed to help alleviate the incidence of chemotherapy-induced myelosuppression in patients who are about to undergo platinum and etoposide-containing or topotecan-containing chemotherapy regimens for extensive-stage small-cell lung cancer. Chemotherapy-induced myelosuppression is a common side effect of chemotherapy, which impacts the production of blood cells and can lead to severe complications such as infections, anemia, and bleeding. By reducing the incidence of myelosuppression, Trilaciclib can help patients to better tolerate chemotherapy and potentially improve their overall treatment outcomes. It is an important addition to the arsenal of treatments for patients battling this devastating disease, and it represents a significant advancement in the fight against cancer.

**Pharmacodynamics:**

Trilaciclib is a medication that has been developed to address the common side effect of chemotherapy-induced myelosuppression in patients with extensive-stage small-cell lung cancer. This side effect occurs when the bone marrow is unable to produce enough blood cells, which can lead to a range of complications. Trilaciclib is effective in reducing the incidence of myelosuppression when administered before chemotherapy regimens that contain platinum, etoposide, or topotecan. It works by protecting the bone marrow cells from the damage caused by chemotherapy. However, it is important to note that Trilaciclib has a short duration of action, which lasts for approximately 16 hours, and a narrow therapeutic index. This means that patients should be closely monitored for any adverse reactions and counseled regarding the risk of injection site reactions, hypersensitivity, and interstitial lung disease. While injection site reactions are common, hypersensitivity reactions are rare but can occur, and interstitial lung disease is a serious side effect that requires medical attention. Overall, Trilaciclib is an important medication that can significantly reduce the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small-cell lung cancer, but patients should be aware of the potential side effects and carefully monitored for any adverse reactions.

**Mechanism of action:**

Trilaciclib is a promising drug that inhibits cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 5 (CDK5) at specific concentrations. CDK4 and CDK5 are expressed in hematopoietic stem cells and progenitor cells, and they play a key role in phosphorylating and inactivating the retinoblastoma protein, which is a tumor suppressor. However, trilaciclib doesn't interfere with the intended chemotherapy-induced cytotoxicity of cancer cells, even in patients with retinoblastoma protein-null small-cell lung cancer. One of the most significant benefits of trilaciclib is that it can lead to a temporary pause in the cell cycle in the G1 phase for approximately 16 hours. This temporary cell cycle arrest helps prevent chemotherapy-induced DNA damage in healthy cells, reducing the activity of caspases 3 and 7, which reduces apoptosis of healthy cells. This means that trilaciclib can protect healthy cells from chemotherapy while still allowing the chemotherapy to kill cancer cells. In addition to its cell cycle effects, trilaciclib has also been shown to enhance T-cell activation, upregulate major histocompatibility complex (MHC) class I and II, and stabilize programmed death-ligand 1 (PD-L1). These activities increase T-cell activity, increase antigen presentation, and sensitize cells to immune checkpoint inhibitors. Overall, trilaciclib has great potential as a cancer treatment that can protect healthy cells from chemotherapy while enhancing the immune system's ability to fight cancer.

**Absorption:**

Trilaciclib is a drug whose absorption increases proportionally with dose, as indicated by its Cmax and AUC values.

**Volume of distribution:** At steady state, the volume of distribution of dinaciclib is 1130 L

**Protein binding:** Data regarding the protein binding of dinaciclib are not readily available

**Metabolism:**

Data regarding the metabolism of dinaciclib are not readily available, however, it is expected to be extensively metabolized

**Route of elimination:**

The drug is eliminated via feces and urine, with 79.1% of a radiolabelled dose recovered in the feces and 14% in the urine.

**Half-life:** 14 h

**Potential Adverse effects:**

1. diarrhea.
2. urinary tract infection.
3. heartburn.
4. headache.
5. stomach pain.
6. loss of hair (alopecia)
7. cough.

**III. APPLICATIONS OF TRILACICLIB IN TREATING CANCER**

trilaciclib is a novel therapy that falls under the category of myeloprotective agents. it works by temporarily inhibiting the activity of the enzyme cyclin-dependent kinase 4/6 (cdk4/6), which plays a crucial role in the cell cycle of bone marrow cells. by halting the cell cycle in hematopoietic stem and progenitor cells (hspcs), trilaciclib helps protect these cells from the damaging effects of chemotherapy. here are some detailed applications or uses of trilaciclib:

1. **chemotherapy-induced myelosuppression management:** trilaciclib is primarily utilized to mitigate the side effects of myelosuppression induced by chemotherapy. myelosuppression refers to a decrease in the production of blood cells by the bone marrow, which commonly occurs as a side effect of chemotherapy. by preserving the bone marrow's ability to produce blood cells, trilaciclib can reduce the severity and duration of myelosuppression, thereby potentially decreasing the risk of infections, anemia, and bleeding complications associated with chemotherapy.

2. **prevention of chemotherapy-induced neutropenia:** neutropenia, a condition characterized by abnormally low levels of neutrophils (a type of white blood cell), is a common and potentially serious side effect of chemotherapy. trilaciclib has been studied for its ability to preserve neutrophil counts during chemotherapy treatment, reducing the

incidence and severity of neutropenia. this can be particularly beneficial in cancer patients undergoing myelosuppressive chemotherapy regimens, where maintaining adequate neutrophil levels is crucial for fighting infections and supporting overall health.

**3. improving tolerance to chemotherapy:** chemotherapy can be physically taxing on patients due to its toxic effects on rapidly dividing cells, including those in the bone marrow. by protecting hematopoietic stem and progenitor cells from chemotherapy-induced damage, trilaciclib may improve patients' tolerance to chemotherapy, allowing for the delivery of more effective and potentially higher doses of chemotherapy while minimizing associated side effects. this could potentially lead to better treatment outcomes and improved quality of life for cancer patients.

**4. facilitating combination chemotherapy regimens:** trilaciclib has been investigated in clinical trials as part of combination chemotherapy regimens for various types of cancer, including small cell lung cancer (sclc) and triple-negative breast cancer (tnbc). incorporating trilaciclib into these regimens aims to enhance the efficacy of chemotherapy by protecting bone marrow function, thus enabling the delivery of more intensive and effective treatment while reducing the risk of hematologic toxicity.

**5. enhancing recovery after chemotherapy:** in addition to its role during chemotherapy administration, trilaciclib may also contribute to faster recovery of bone marrow function following chemotherapy cycles. by minimizing the duration and severity of myelosuppression, trilaciclib may help patients recover their blood cell counts more quickly between treatment cycles, allowing for more timely and effective subsequent doses of chemotherapy.

#### IV. CONCLUSION

trilaciclib emerges as a promising agent in the landscape of cancer treatment, offering a multifaceted approach to mitigating the debilitating side effects of chemotherapy-induced myelosuppression. its unique mechanism of action, coupled with its demonstrated efficacy in clinical trials, positions it as a valuable tool in enhancing patient outcomes and quality of life. by preserving bone marrow function and minimizing hematologic toxicity, trilaciclib not only enables more effective delivery of chemotherapy but also fosters a quicker recovery process post-treatment. as a first-in-class medication, its approval marks a significant milestone in cancer therapeutics, heralding a new era of supportive care for patients undergoing chemotherapy. moving forward, continued research and clinical utilization of trilaciclib hold promise for further refining cancer treatment protocols and improving the overall patient experience in the fight against cancer.

#### REFERENCES

1. Indian Pharmacopoeia, Ministry of Health & Family Welfare, Government of India, New Delhi, 1996.
2. The United States Pharmacopoeia- the National Formulary, United States Pharmacopoeial Convention, Rockville, 2007.
3. Malvia R, Bansal V, Pal O.P and Sharma P.K. A Review of High Performance Liquid Chromatography. Journal of Global Pharma Technology (2010)
4. Douglas A Skoog, F. James Holler, Timothy A. Niemen, Principles of Instrumental Analysis Pg 725-760.
5. Dr.S. Ravi Shankar, Textbook of Pharmaceutical analysis, Fourth edition, Pg 13.1-13.2
6. David G.Watson. Pharmaceutical Analysis, A textbook for Pharmacy Students and Pharmaceutical Chemists. Harcourt Publishers Limited; 2nd Ed., Pg 221-232.
7. Remington's The Sciences and Practise of Pharmacy, 20th Edition (2000)
8. Connors Ka. A Textbook of Pharmaceutical Analysis, Wiley Intersciences Inc; Delhi, 3rd Ed, Pg 373-421, (1994)
9. Gurdeep R.Chatwal, Sham K . Anand, Instrumental Methods of Chemical Analysis, Pg 2.566-2.638 (2007)
10. Nasal. A, Siluk.D, and Kaliszan.R. Chromatographic Retention Parameters in Medicinal Chemistry and Pharmacology, Pubmed, Vol.10, Issue 5 Pg no-381-426, March (2003)
11. Ashok Kumar, Lalith Kishore, Navpreet Kaur , Anoop Nair. Method Development and Validation for Pharmaceutical Analysis. International Pharmaceutica Scientia, Vol 2, Issue 3, Jul-Sep (2012)
12. Kaushal. C, Srivatsava. B, A Process of Method Development: A Chromatographic Approach. J Chem Pharm Res, Vol.2, Issue 2, 519-545, (2010)
13. Green JM. A Practical guide to analytical method validation, Anal Chem (1996) 305A-309A
14. ICH, Validation of analytical procedures: Text and Methodology. International Conference on Harmonization, ICPMA , Geneva , (1996)
15. IUPAC. Compendium of Chemical Terminology, 2nd edn. (The Gold Book). PAC69, 1137 (1997). Glossary of

terms used in computational drug design (IUPAC Recommendations).

16. K. D. Tripathi, Essentials of Medical Pharmacology, 6th Edition, Jaypee brother's medical publishers (P) LTD, p-254-255.
17. Indian Pharmacopoeia, Indian Pharmacopoeial Commission, Controller of Publication, Government of India, Ministry of health and Family Welfare, Ghaziabad, India, 2 (2010) 1657-1658.
18. British Pharmacopoeia, The British Pharmacopoeial Commission, the stationary office, UK, London, 1408-1409 2 (2011).
19. <https://go.drugbank.com/drugs/DB09185>
20. <https://pubchem.ncbi.nlm.nih.gov/compound/Trilaciclib>
21. **Ramchandran D et al.**, STABILITY INDICATING AND COST EFFECTIVE ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF TRILACICLIB BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, JCDR. 2021; 12(4): 1403-1412.
22. **E. Manuela P. J. Garrido et al.**, Voltammetric and DFT Studies on Trilaciclib: Analytical Application to Pharmaceuticals and Biological Fluids Electroanalysis 20, 2008, No. 13, 1454 – 1462
23. **Chungping Yu et al** ew Insights into the Mechanism of Action of Trilaciclib: Serotonin and Norepinephrine Modulating Properties, [J Exp Pharmacol](#). 2020; 12: 285–300
24. <https://go.drugbank.com/drugs/DB15442>



INTERNATIONAL  
STANDARD  
SERIAL  
NUMBER  
INDIA



# INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

 9940 572 462  6381 907 438  [ijirset@gmail.com](mailto:ijirset@gmail.com)



[www.ijirset.com](http://www.ijirset.com)

Scan to save the contact details